Lexaria receives USD million Australian tax rebate cash payment
Lexaria Bioscience Corp. says it has received a cash tax rebate payment related to its 2025 Australian human study results.
Lexaria's 2025 Australian human study results in a USD$2.6 million cash rebateKELOWNA, BC / / September 1, 2026 / Lexaria Bioscience Corp.
NASDAQ:LEXX ("Lexaria" or the "Company"), a global innovator in oral drug delivery platforms, is pleased to announce that it has received a cash…